• Rezolute highlighted ersodetug, an IV monoclonal antibody targeting the insulin receptor for refractory hypoglycemia across hyperinsulinism types.
• Phase 3 sunRIZE in congenital hyperinsulinism completed; open-label extension ongoing with 100% rollover and high retention.
• Primary SMBG endpoint missed due to functional unblinding; multiple CGM measures showed clinically meaningful hypoglycemia reductions.
• FDA review of analysis datasets ongoing; program update expected in 2H 2026, with topline data targeted for Q1 2027.
• Cash position cited at USD 120 million, with runway to mid-2028; company framed a USD 1 billion-plus global market opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.